Low-Grade Glioma Market Report 2026
Download Free Sample Buy Now
Low-Grade Glioma Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Low-Grade Glioma Market Report 2026

Global Outlook – By Drug Type (Trametinib, Dabrafenib, Ivosidenib, Mirdametinib), By Treatment (Surgery, Chemotherapy, Radiation), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Low-Grade Glioma Market Overview

• Low-Grade Glioma market size has reached to $1.47 billion in 2025

• Expected to grow to $1.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%

• Growth Driver: Rising Incidence Of Brain Tumours Influences The Market Growth

• Market Trend: Advancements In Low-Grade Glioma Treatment

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Low-Grade Glioma Market?

Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.

The main drug types of low-grade glioma are trametinib, dabrafenib, ivosidenib, and mirdametinib. Trametinib is a medication used to treat certain types of cancer by inhibiting the MEK1/2 proteins involved in cancer cell growth. Low-grade glioma treatment generally includes a combination of surgery, chemotherapy, and radiation. Medications are delivered through various routes, including oral and topical administration, and are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Low-Grade Glioma Market Global Report 2026 Market Report bar graph

What Is The Low-Grade Glioma Market Size and Share 2026?

The low-grade glioma market size has grown strongly in recent years. It will grow from $1.47 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to advancements in neuroimaging technologies, improved survival rates in low-grade glioma patients, increased neurosurgical intervention rates, growing awareness of brain tumor symptoms, expansion of oncology treatment centers.

What Is The Low-Grade Glioma Market Growth Forecast?

The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing focus on molecular tumor profiling, rising investment in targeted oncology drugs, growing demand for less aggressive treatment options, expanding access to specialized neuro-oncology care, ongoing clinical trials for novel therapies. Major trends in the forecast period include rising focus on early diagnosis and monitoring, growing adoption of targeted drug therapies, increasing preference for multimodal treatment approaches, expansion of personalized treatment planning, rising long-term disease management strategies.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Low-Grade Glioma Market Segmentation

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)

2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)

3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy

4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

What Is The Driver Of The Low-Grade Glioma Market?

The rising incidence of brain tumors is expected to propel the growth of the low-grade glioma market going forward. A brain tumor is an abnormal growth of cells in the brain or surrounding areas, which can be benign or malignant. The rising incidence of brain tumors is due to factors such as increased exposure to radiation, environmental pollutants, genetic predisposition, and aging. Low-grade glioma is helpful for brain tumors by utilizing advanced diagnostic techniques and targeted therapies such as surgery, radiation, and chemotherapy, which help slow tumor progression, preserve neurological function, and improve patient outcomes, making early detection and personalized treatment crucial for managing other brain tumors with similar growth patterns. For instance, in October 2025, according to the Cancer Australia, an Australia-based government agency, in 2023, Australia recorded 1,597 deaths from brain cancer (956 men and 641 women). By 2025, this number is expected to rise slightly to 1,639 deaths (979 men and 660 women). The estimated risk of dying from brain cancer by age 85 in 2025 is 1 in 195 (0.51%), with the risk higher for males at 1 in 165 (0.61%) and lower for females at 1 in 240 (0.42%). Therefore, the rising incidence of brain tumors is driving the growth of the low-grade glioma industry.

Key Players In The Global Low-Grade Glioma Market

Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

Global Low-Grade Glioma Market Trends and Insights

Major companies operating in the low-grade glioma market are focusing on the integration of combination therapies and targeted therapy, such as genetic alteration drugs, to gain a competitive edge and enhance the treatment of children with low-grade glioma. Genetic alteration drugs are targeted therapies designed to modify or inhibit specific genetic mutations or abnormalities in cells, helping to treat diseases such as cancer by blocking the pathways that drive uncontrolled cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after receiving accelerated FDA approval. This targeted therapy is designed for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) with BRAF gene alterations. Offering a convenient once-weekly oral treatment, it addresses a crucial need for pediatric LGG patients with limited prior treatment options.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Low-Grade Glioma Market?

In July 2024, Ipsen Biopharmaceuticals Inc., a US-based pharmaceutical company, collaborated with Day One Biopharmaceuticals Inc. to commercialize tovorafenib for pediatric low-grade glioma (pLGG) with BRAF mutations. This collaboration aims to expand global access to the treatment while leveraging Ipsen’s oncology expertise and international reach to accelerate regulatory and commercial efforts outside the US. Day One Biopharmaceuticals is a US-based clinical-stage biopharmaceutical company that is primarily focused on developing targeted therapies for pediatric low-grade glioma.

Regional Outlook

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Low-Grade Glioma Market?

The low-grade glioma market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, and targeted therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The low-grade glioma market also includes sales of astrocytomas, oligodendrogliomas, and ependymomas. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Low-Grade Glioma Market Report 2026?

The low-grade glioma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the low-grade glioma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Low-Grade Glioma Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $1.56 billion
Revenue Forecast In 2035 $1.94 billion
Growth Rate CAGR of 5.9% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drug Type, Treatment, Distribution Channel
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Low-Grade Glioma Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Low-Grade Glioma Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Low-Grade Glioma Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Low-Grade Glioma Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Rising Focus On Early Diagnosis And Monitoring

4.2.2 Growing Adoption Of Targeted Drug Therapies

4.2.3 Increasing Preference For Multimodal Treatment Approaches

4.2.4 Expansion Of Personalized Treatment Planning

4.2.5 Rising Long-Term Disease Management Strategies

5. Low-Grade Glioma Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Cancer Treatment Centers

5.3 Neurology Clinics

5.4 Specialty Oncology Clinics

5.5 Academic And Research Institutions

6. Low-Grade Glioma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Low-Grade Glioma Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Low-Grade Glioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Low-Grade Glioma Market Size, Comparisons And Growth Rate Analysis

7.3. Global Low-Grade Glioma Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Low-Grade Glioma Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Low-Grade Glioma Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Low-Grade Glioma Market Segmentation

9.1. Global Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

9.2. Global Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Surgery, Chemotherapy, Radiation

9.3. Global Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

9.4. Global Low-Grade Glioma Market, Sub-Segmentation Of Trametinib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)

9.5. Global Low-Grade Glioma Market, Sub-Segmentation Of Dabrafenib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)

9.6. Global Low-Grade Glioma Market, Sub-Segmentation Of Ivosidenib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy

9.7. Global Low-Grade Glioma Market, Sub-Segmentation Of Mirdametinib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy

10. Low-Grade Glioma Market Regional And Country Analysis

10.1. Global Low-Grade Glioma Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Low-Grade Glioma Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Low-Grade Glioma Market

11.1. Asia-Pacific Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Low-Grade Glioma Market

12.1. China Low-Grade Glioma Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Low-Grade Glioma Market

13.1. India Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Low-Grade Glioma Market

14.1. Japan Low-Grade Glioma Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Low-Grade Glioma Market

15.1. Australia Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Low-Grade Glioma Market

16.1. Indonesia Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Low-Grade Glioma Market

17.1. South Korea Low-Grade Glioma Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Low-Grade Glioma Market

18.1. Taiwan Low-Grade Glioma Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Low-Grade Glioma Market

19.1. South East Asia Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Low-Grade Glioma Market

20.1. Western Europe Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Low-Grade Glioma Market

21.1. UK Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Low-Grade Glioma Market

22.1. Germany Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Low-Grade Glioma Market

23.1. France Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Low-Grade Glioma Market

24.1. Italy Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Low-Grade Glioma Market

25.1. Spain Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Low-Grade Glioma Market

26.1. Eastern Europe Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Low-Grade Glioma Market

27.1. Russia Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Low-Grade Glioma Market

28.1. North America Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Low-Grade Glioma Market

29.1. USA Low-Grade Glioma Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Low-Grade Glioma Market

30.1. Canada Low-Grade Glioma Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Low-Grade Glioma Market

31.1. South America Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Low-Grade Glioma Market

32.1. Brazil Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Low-Grade Glioma Market

33.1. Middle East Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Low-Grade Glioma Market

34.1. Africa Low-Grade Glioma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Low-Grade Glioma Market, Segmentation By Drug Type, Segmentation By Treatment, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Low-Grade Glioma Market Regulatory and Investment Landscape

36. Low-Grade Glioma Market Competitive Landscape And Company Profiles

36.1. Low-Grade Glioma Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Low-Grade Glioma Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Low-Grade Glioma Market Company Profiles

36.3.1. F Hoffmann La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis

37. Low-Grade Glioma Market Other Major And Innovative Companies

Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc

38. Global Low-Grade Glioma Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Low-Grade Glioma Market

40. Low-Grade Glioma Market High Potential Countries, Segments and Strategies

40.1 Low-Grade Glioma Market In 2030 - Countries Offering Most New Opportunities

40.2 Low-Grade Glioma Market In 2030 - Segments Offering Most New Opportunities

40.3 Low-Grade Glioma Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Low-Grade Glioma Market, Overview Of Key Products - Product Examples
  • Table 2: Global Low-Grade Glioma Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Low-Grade Glioma Market, Supply Chain Analysis
  • Table 4: Global Low-Grade Glioma Market, Major Raw Material Providers
  • Table 5: Global Low-Grade Glioma Market, Major Resource Providers
  • Table 6: Global Low-Grade Glioma Market, Major Manufacturers (Suppliers)
  • Table 7: Global Low-Grade Glioma Market, Major Distributors And Channel Partners
  • Table 8: Global Low-Grade Glioma Market, Key Technologies & Future Trends
  • Table 9: Global Low-Grade Glioma Market, Major Trends
  • Table 10: Global Low-Grade Glioma Market, Major End Users
  • Table 11: Global Low-Grade Glioma Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Low-Grade Glioma Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Low-Grade Glioma Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Low-Grade Glioma Market - TAM, US$ Billion, 2025
  • Table 15: Global Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Low-Grade Glioma Market, Sub-Segmentation Of Trametinib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Low-Grade Glioma Market, Sub-Segmentation Of Dabrafenib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Low-Grade Glioma Market, Sub-Segmentation Of Ivosidenib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Low-Grade Glioma Market, Sub-Segmentation Of Mirdametinib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Low-Grade Glioma Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Low-Grade Glioma Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Global Low-Grade Glioma Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 97: Global Low-Grade Glioma Market - Company Scoring Matrix
  • Table 98: F Hoffmann La Roche Ltd Financial Performance
  • Table 99: Novartis AG Financial Performance
  • Table 100: AstraZeneca PLC Financial Performance
  • Table 101: Bristol Myers Squibb Company Financial Performance
  • Table 102: Merck & Co Inc Financial Performance
  • Table 103: Global Low-Grade Glioma Market, Competitive Benchmarking (In USD Billions)
  • Table 104: Global Low-Grade Glioma Market, Competitive Dashboard
  • Table 105: Global Low-Grade Glioma Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 106: Global, Low-Grade Glioma Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030
  • Table 107: Global, Low-Grade Glioma Market Size Gain ($ Billion), Segmentation By Treatment, 2025 – 2030
  • Table 108: Global, Low-Grade Glioma Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Low-Grade Glioma Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Low-Grade Glioma Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Low-Grade Glioma Market, Supply Chain Analysis
  • Figure 4: Global Low-Grade Glioma Market, Major Raw Material Providers
  • Figure 5: Global Low-Grade Glioma Market, Major Resource Providers
  • Figure 6: Global Low-Grade Glioma Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Low-Grade Glioma Market, Major Distributors And Channel Partners
  • Figure 8: Global Low-Grade Glioma Market, Key Technologies & Future Trends
  • Figure 9: Global Low-Grade Glioma Market, Major Trends
  • Figure 10: Global Low-Grade Glioma Market, Major End Users
  • Figure 11: Global Low-Grade Glioma Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Low-Grade Glioma Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Low-Grade Glioma Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Low-Grade Glioma Market - TAM, US$ Billion, 2025
  • Figure 15: Global Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Low-Grade Glioma Market, Sub-Segmentation Of Trametinib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Low-Grade Glioma Market, Sub-Segmentation Of Dabrafenib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Low-Grade Glioma Market, Sub-Segmentation Of Ivosidenib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Low-Grade Glioma Market, Sub-Segmentation Of Mirdametinib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Low-Grade Glioma Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Low-Grade Glioma Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Low-Grade Glioma Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Low-Grade Glioma Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Low-Grade Glioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Global Low-Grade Glioma Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 97: Global Low-Grade Glioma Market - Company Scoring Matrix
  • Figure 98: F Hoffmann La Roche Ltd Financial Performance
  • Figure 99: Novartis AG Financial Performance
  • Figure 100: AstraZeneca PLC Financial Performance
  • Figure 101: Bristol Myers Squibb Company Financial Performance
  • Figure 102: Merck & Co Inc Financial Performance
  • Figure 103: Global Low-Grade Glioma Market, Competitive Benchmarking (In USD Billions)
  • Figure 104: Global Low-Grade Glioma Market, Competitive Dashboard
  • Figure 105: Global Low-Grade Glioma Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 106: Global, Low-Grade Glioma Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030
  • Figure 107: Global, Low-Grade Glioma Market Size Gain ($ Billion), Segmentation By Treatment, 2025 – 2030
  • Figure 108: Global, Low-Grade Glioma Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Glioma Treatment Market Report 2026 - Global Outlook – By Type (Low-Grade, High-Grade), By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases), By Route Of Administrati...

Adult Malignant Glioma Therapeutics Market Report 2026 - Global Outlook – By Type Of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types), By T...

Glioblastoma Multiforme Market Report 2026 - Global Outlook – By Drug Class (Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes), By Diagnostic Tools (Magnetic Resonance Imaging (MRI), Computed ...

Pontine Glioma Drugs Market Report 2026 - Global Outlook – By Type (Diffuse Brain Stem Glioma, Focal Brain Stem Glioma, Recurrent Brain Stem Glioma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Appli...

Acoustic Neuroma Market Report 2026 - Global Outlook – By Type (Unilateral Vestibular Schwannomas, Bilateral Vestibular Schwannomas), By Treatment Type (Radiation Therapy, Proton Therapy, Stereotactic Radiosurgery), By D...

Glioblastoma Multiforme (GBM) Treatment Market Report 2026 - Global Outlook – By Treatment (Surgery, Radiation Therapy, Chemotherapy, R Immunotherapy), By Drug Class (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafe...

Paraganglioma Market Report 2026 - Global Outlook – By Type (Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Carotid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, ...

Brain Tumor Drugs Market Report 2026 - Global Outlook – By Drugs (Temozolomide, Bevacizumab, Other Drugs), By End User (Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users), By Mechanism of Action (Che...

Frequently Asked Questions

The Low-Grade Glioma market was valued at $1.47 billion in 2025, increased to $1.56 billion in 2026, and is projected to reach $1.94 billion by 2030.

The global Low-Grade Glioma market is expected to grow at a CAGR of 5.6% from 2026 to 2035 to reach $1.94 billion by 2035.

Some Key Players in the Low-Grade Glioma market Include, F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc .

Major trend in this market includes: Advancements In Low-Grade Glioma Treatment. For further insights on this market. request a sample here

North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us